Company Profile

Onconova Therapeutics Inc
Profile last edited on: 2/15/2022      CAGE: 3EU71      UEI: GJ6DXMXLPB21

Business Identifier: Small molecule cancer therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

12 Penns Trail
Newtown, PA 18940
   (267) 759-3680
Location: Multiple
Congr. District: 01
County: Bucks

Public Profile

Active in the SBIR arena in the period 2003-2011, Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company structured around discovery and developy of novel cancer treatment products. Having proprietary, targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation, the firm's novel proprietary multi-kinase inhibitor -- ON 123300 -- targets CDK4/6 and other tyrosine kinases. The firm's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. More recently, the firm has been it involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconov

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 1 NIH $275,861
Project Title: Development of a Selective Plk2 Inhibitor for Cancer Therapy
2008 1 NIH $220,180
Project Title: Development Of A Small Molecule-Targeted Therapy For Mantle Cell Lymphoma
2007 1 NIH $155,103
Project Title: Evaluation of novel cytotoxic compounds for immunoconjugates
2007 1 NIH $203,744
Project Title: Identification of Small Pharmacologic Inhibitors of HIV-1 Replication
2006 2 NIH $845,713
Project Title: Use of Novel Cox-2 Inhibitors in Neurological Disorders

Key People / Management

  Steven Fruchtman -- President and CEO

  Ramesh Kumar -- Advisor: Co-Founder Former President and CEO

  Thomas J McKearn -- President, Research and Development

  James R Altland

  Stanley C Bell

  Xavier Grana

  Mark Patrick Guerin -- Chief Financial Officer

  L Kuprewicz

  Anoj Maniar -- Senior Vice President, Product Development

  Scott Megafinn -- Senior Vice President, Commercial

  Ric Woodman -- Chief Medical Officer and Senior Vice President of Research and Development